Because of all of the typical concerns with well known long term glucocorticoids side effects, we plan to study the effectiveness of transient and/or intermittent DEX therapy with immune checkpoint blockade in these LKB1 mutant NSCLC preclinical models. The gene discussed is STK11; the disease is non-small cell lung carcinoma.